Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-8.06%
$5.28
0% positive prob.
5-Day Prediction
-13.27%
$4.98
0% positive prob.
20-Day Prediction
-10.03%
$5.16
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q4 2025 | SELL | -8.06% | -13.27% | -10.03% | 100.0% | Pending |
| Q3 2025 | SELL | -7.02% | -13.91% | -10.08% | 100.0% | -8.81% |
SEC 8-K filings with transcript text
Mar 12, 2026 · 100% conf.
1D
-8.06%
$5.28
Act: +6.27%
5D
-13.27%
$4.98
20D
-10.03%
$5.16
csbr-202603120000771856false00007718562026-03-122026-03-12
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): March 12, 2026
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On March 12, 2026, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its third quarter ended January 31, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated March 12, 2026
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 12, 2026 By:/s/ Robert Brainin Robert Brainin Chief Executive Officer
Dec 15, 2025 · 100% conf.
1D
-7.02%
$7.39
Act: -15.35%
5D
-13.91%
$6.84
Act: -8.81%
20D
-10.08%
$7.15
Act: -9.69%
csbr-202512150000771856false00007718562025-12-152025-12-15
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): December 15, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On December 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its second quarter ended October 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated December 15, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 15, 2025 By:/s/ Robert Brainin Robert Brainin Chief Executive Officer
Sep 15, 2025
csbr-202509150000771856false00007718562025-09-152025-09-15
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): September 15, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On September 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated September 15, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: September 15, 2025 By:/s/ Robert Brainin Robert Brainin Chief Executive Officer
Jul 23, 2025
csbr-202507230000771856false00007718562025-07-232025-07-23
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): July 23, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On July 23, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated July 23, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: July 23, 2025By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Mar 11, 2025
csbr-202503110000771856false00007718562025-03-112025-03-11
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): March 11, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On March 11, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its third quarter ended January 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated March 11, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 11, 2025 By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Dec 11, 2024
csbr-202412110000771856false00007718562024-12-112024-12-11
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): December 11, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On December 11, 2024, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its second quarter ended October 31, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated December 11, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 11, 2024 By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Sep 11, 2024
csbr-202409110000771856false00007718562024-09-112024-09-11
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): September 11, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On September 11, 2024, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated September 11, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 12, 2024By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Jul 18, 2024
csbr-202407180000771856false00007718562024-07-182024-07-18
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): July 18, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On July 18, 2024, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated July 18, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: July 18, 2024By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Mar 12, 2024
csbr-202403120000771856false00007718562024-03-122024-03-12
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): March 12, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On March 12, 2024, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its third quarter ended January 31, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated March 12, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 12, 2024By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Dec 12, 2023
csbr-202312120000771856false00007718562023-12-122023-12-12
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): December 12, 2023
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On December 12, 2023, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its second quarter ended October 31, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated December 12, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 12, 2023By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Sep 13, 2023
csbr-202309130000771856false00007718562023-09-132023-09-13
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): September 13, 2023
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On September 13, 2023, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated September 13, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: September 13, 2023By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Jul 24, 2023
csbr-202307240000771856false00007718562023-07-242023-07-24
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): July 24, 2023
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On July 24, 2023, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated July 24, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: July 21, 2022By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Mar 15, 2023
csbr-202303150000771856FALSE00007718562023-03-152023-03-15
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): March 15, 2023
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On March 15, 2023, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its third quarter ended January 31, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release Dated March 15, 2023
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
March 15, 2023By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Dec 13, 2022
csbr-202212130000771856FALSE00007718562022-12-132022-12-13
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): December 13, 2022
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On December 13, 2022, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its fiscal quarter ended October 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release Dated December 13, 2022
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
December 13, 2022By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Sep 8, 2022
csbr-202209080000771856FALSE00007718562022-09-082022-09-08
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): September 8, 2022
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On September 8, 2022, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its fiscal quarter ended July 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release Dated September 8, 2022
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
September 8, 2022By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Jul 21, 2022
8-K 1 csbr8-k4302022.htm 8-K
Document
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): July 21, 2022
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On July 21, 2022, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated July 21, 2022
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: July 21, 2022By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Mar 15, 2022
csbr-202203150000771856FALSE00007718562022-03-152022-03-15
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): March 15, 2022
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On March 15, 2022, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its fiscal quarter ended January 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release Dated March 15, 2022
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
March 15, 2022By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Dec 13, 2021
csbr-202112130000771856FALSE00007718562021-12-132021-12-13
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): December 13, 2021
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On December 13, 2021, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its fiscal quarter ended October 31, 2021. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release Dated December 13, 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
December 13, 2021By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Sep 13, 2021
csbr-202109130000771856FALSE00007718562021-09-132021-09-13
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): September 13, 2021
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On September 13, 2021, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its fiscal quarter ended July 31, 2021. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release Dated September 13, 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
September 13, 2021By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
Jul 22, 2021
csbr-202107220000771856false00007718562021-07-222021-07-22
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): July 22, 2021
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On July 22, 2021, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2021. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated July 22, 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: July 22, 2021By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
This page provides Champions Oncology Inc. (CSBR) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CSBR's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.